Blaine Labs Recalls Wound Care Gel Nationwide Over Microbial Contamination Risk

Blaine Labs, Inc. has initiated a voluntary nationwide recall of its Wound Care Gel products, a critical move prompted by the discovery of microbial contamination. The recall targets three specific lot numbers of the 1 oz. and 3 oz. gels, which contain 0.1% Benzalkonium Chloride, and extends directly to the consumer level. This action signals a significant quality control failure for a product intended for wound management, where sterility is paramount to prevent serious infections.

The California-based company announced the recall on April 7, 2026, from its Santa Fe Springs location. The affected products are designed for topical wound care, making the presence of microbial contamination a direct threat to patient safety. The recall to the consumer level indicates the products may already be in homes and medicine cabinets, requiring immediate public awareness and action to return or dispose of the compromised gels.

This incident places Blaine Labs under immediate regulatory and public scrutiny. The use of a contaminated product on open wounds raises the risk of localized or systemic infections, particularly in vulnerable populations. The voluntary nature of the recall does not lessen the potential liability or the pressure from the FDA, which monitors all such safety alerts through its MedWatch system. The event underscores persistent vulnerabilities in the manufacturing and quality assurance processes within the medical supply sector, potentially impacting consumer trust and inviting stricter oversight.